You are here

Article Text

Article menu
Download PDFPDF
Learning from errors
CASE REPORT
Inflammatory optic disc neovascularisation managed with oral steroids/immunosuppressants and intravitreal ranibizumab
  1. Babu Lal Kumawat,
  2. Rohan Chawla,
  3. Pradeep Venkatesh,
  4. Koushik Tripathy
  1. Department of Ophthalmology, All India Institute of Medical Sciences, New Delhi, India
  1. Correspondence to Dr Koushik Tripathy, koushiktripathy{at}gmail.com

Summary

Inflammatory optic disc neovascularisation (NVD) has been treated with periocular or systemic steroids, immunosuppressants, panretinal photocoagulation and bevacizumab. However, the role of intravitreal ranibizumab in inflammatory NVD has not been explored in the peer-reviewed indexed literature. In case 1, NVD and associated subhyaloid haemorrhage showed rapid and dramatic regression after intravitreal ranibizumab. Recurrence was noted 8 weeks after injection which was managed by oral steroids. In case 2, intravitreal ranibizumab led to partial resolution of NVD. The addition of steroids, azathioprine and panretinal photocoagulation led to further fibrosis of the neovascularisation. Ranibizumab may be an important adjunct to anti-inflammatory therapy in the management of inflammatory NVD.

  • retina
  • ophthalmology

https://doi.org/10.1136/bcr-2017-222262

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors BLK and RC had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. KT and BLK were responsible for acquisition of data. RC and PV provided administrative, technical and material support, and supervised the study. All the authors were involved in study concept and design, analysis and interpretation of data, drafting of the manuscript and critical revision of the manuscript for important intellectual content.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.